Psybio Therapeutics Corp
XTSX:PSYB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (16), the stock would be worth CA$-0.71 (7 165% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | CA$0.01 |
0%
|
| Industry Average | 16 | CA$-0.71 |
-7 165%
|
| Country Average | 22 | CA$-0.97 |
-9 835%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
P
|
Psybio Therapeutics Corp
XTSX:PSYB
|
809k CAD | -0.2 | -0.1 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.7B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
99.6B ZAR | 15.4 | 10.3 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.4B USD | -87 522.9 | 38 074.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
57.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.3B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.3B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.5B USD | 45.5 | -3 268.5 | |
| US |
Q
|
Qnity Electronics Inc
NYSE:Q
|
29.6B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 22 |
| 70th Percentile | 36 |
| Max | 116 589.8 |
Other Multiples
Psybio Therapeutics Corp
Glance View
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-02-08. The firm is developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The firm is in the process of developing its portfolio of product candidates for sale in the pharmaceutical industry. The company has developed a technology platform that enables the generation of its formulation for its lead compound psilocybin, biosynthetic psilocybin, and other targeted tryptamines through a biosynthetic process using genetically modified bacteria through collaboration with Miami University-based in Oxford, Ohio. The firm utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
